UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June 30, 2022~~March 31, 2023


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to _______________

Commission File Number 001-35521

CLEARSIGN TECHNOLOGIES CORPORATION

(Exact name of registrant as specified in its charter)


Washington (State or other jurisdiction of incorporation or organization)		26-2056298 (I.R.S. Employer Identification No.)

8023 E. 63rd Place, Suite 101

Tulsa, Oklahoma 74133

(Address of principal executive offices)

(Zip Code)

~~(206) 673-4848~~(918) 236-6461

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Common Stock	CLIR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period than the registrant was required to submit such files). Yes ⌧ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐

Non-accelerated filer ⌧		Smaller reporting company ☒

		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ⌧

As of ~~August 1, 2022,~~May 10, 2023, the issuer has ~~37,951,559~~38,545,556 shares of common stock, par value $0.0001, issued and outstanding.

Table of Contents

TABLE OF CONTENTS


~~June 30, 2022~~PART I	FINANCIAL INFORMATION

Item 1.	Unaudited Condensed Consolidated Financial Statements

	Unaudited Condensed Consolidated Balance Sheets as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021~~2022	1

	Unaudited Condensed Consolidated Statements of Operations for the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022 ~~and, 2021~~	2

	Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the three ~~month periods during the six~~ months ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~	3

	Unaudited Condensed Consolidated Statements of Cash Flows for the ~~six~~three months ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~	54

	Notes to Unaudited Condensed Consolidated Financial Statements	65

Item 2.	Management’s Discussion and Analysis of Financial Conditions and Results of Operations	2019

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2524

Item 4.	Controls and Procedures	2524

PART II	OTHER INFORMATION	2625

Item 1.	Legal Proceedings	2625

Item 1A.	Risk Factors	2625

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2726

Item 3.	Defaults Upon Senior Securities	2726

Item 4.	Mine Safety Disclosures	2726

Item 5.	Other Information	2726

Item 6.	Exhibits	27

	SIGNATURES	2928

Table of Contents

PART I-FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ClearSign Technologies Corporation and Subsidiary

Condensed Consolidated Balance Sheets

(Unaudited)


(in thousands, except share and per share data)	June 30,		December 31,		March 31,		December 31,
	2022		2021		2023		2022
ASSETS

Current Assets:
Cash and cash equivalents	$	9,007	$	7,607	$	5,328	$	6,451
Short-term held-to-maturity investments						3,161		2,606
Accounts receivable, net				33		50		79
Contract assets		486		39		4		20
Prepaid expenses and other assets		605		345		317		577
Total current assets		10,098		8,024		8,860		9,733

Fixed assets, net		477		530		515		384
Patents and other intangible assets, net		812		799		782		798
Other assets		10		10		10		10

Total Assets	$	11,397	$	9,363	$	10,167	$	10,925

LIABILITIES AND EQUITY

Current Liabilities:
Accounts payable and accrued liabilities	$	356	$	224	$	398	$	296
Current portion of lease liabilities		227		205		77		133
Accrued compensation and related taxes		285		218		253		471
Contract liabilities		84		84		639		247
Total current liabilities		952		731		1,367		1,147
Long Term Liabilities:
Long term lease liabilities		252		350		213		226
Total liabilities		1,204		1,081		1,580		1,373

Commitments and contingencies (note 7)
Commitments and contingencies (Note 7)

Stockholders’ Equity:
Preferred stock, $0.0001 par value, 0 shares issued and outstanding		—		—
Common stock, $0.0001 par value, 36,349,881 and 31,581,666 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively		4		3
Preferred stock, $0.0001 par value, zero shares issued and outstanding						—		—
Common stock, $0.0001 par value, 38,545,556 and 38,023,701 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively						4		4
Additional paid-in capital		96,083		91,035		98,543		98,079
Accumulated other comprehensive income (loss)		(1)		9
Accumulated other comprehensive loss						(8)		(8)
Accumulated deficit		(85,893)		(82,765)		(89,952)		(88,523)
Total ClearSign Technologies Corporation stockholders' equity		10,193		8,282
Noncontrolling Interest		—		—
Total equity		10,193		8,282		8,587		9,552

Total Liabilities and Equity	$	11,397	$	9,363	$	10,167	$	10,925

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

ClearSign Technologies Corporation and Subsidiary

Condensed Consolidated Statements of Operations

(Unaudited)


(in thousands, except share and per share data)	For the Three Months Ended				For the Six Months Ended				For the Three Months Ended
	June 30,				June 30,				March 31,
	2022		2021		2022		2021		2023		2022

Revenues	$	—	$	—	$	—	$	363	$	894	$	—
Cost of goods sold		—		505		—		730		788		—

Gross loss		—		(505)		—		(367)
Gross profit										106		—

Operating expenses:
Research and development		188		472		296		1,298		160		108
General and administrative		1,472		1,565		2,881		2,898		1,650		1,409

Total operating expenses		1,660		2,037		3,177		4,196		1,810		1,517

Loss from operations		(1,660)		(2,542)		(3,177)		(4,563)		(1,704)		(1,517)

Other income
Gain on forgiveness of debt		—		251		—		251
Interest, net										58		—
Government assistance										93		—
Gain from sale of assets		14		—		37		—		5		23
Other income, net		8				12		—		119		4
Total other income		22		251		49		251		275		27

Net loss		(1,638)		(2,291)		(3,128)		(4,312)		(1,429)		(1,490)
Net loss attributed to non-controlling interest		—		1		—		—
Net Loss	$	(1,638)	$	(2,290)	$	(3,128)	$	(4,312)

Net loss per share - basic and fully diluted	$	(0.05)	$	(0.07)	$	(0.09)	$	(0.14)	$	(0.04)	$	(0.05)

Weighted average number of shares outstanding - basic and fully diluted		33,541,408		31,314,816		33,378,054		30,922,871		38,262,710		31,826,221

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

ClearSign Technologies Corporation and Subsidiary

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

For the Three ~~Month Periods During The Six~~ Months Ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~


										Total ClearSign
						Accumulated Other				Technologies Corp.
(in thousands, except per share data)	Common Stock			Additional		Comprehensive		Accumulated		Stockholders’
	Shares	Amount		Paid-In Capital			Income (Loss)	Deficit		Equity
Balances at December 31, 2022	38,023	$	4	$	98,079	$	(8)	$	(88,523)	$	9,552
Share based compensation	223		—		227		—		—		227
Fair value of stock issued in payment of accrued compensation	296		—		234		—		—		234
Shares issued for services ($0.66 per share)	4		—		3		—		—		3
Net loss	—		—		—		—		(1,429)		(1,429)
Balances at March 31, 2023	38,546	$	4	$	98,543	$	(8)	$	(89,952)	$	8,587

Total ClearSign

Accumulated Other

Technologies Corp.
(in thousands, except per share data)

Common Stock

Additional

Comprehensive

Accumulated

Stockholders’

Shares

Amount

Paid-In Capital


Income (loss)

Deficit

Equity
Balances at December 31, 2021

31,582

$
3

$
91,035

$
9

$
(82,765)

$
8,282
Shares issued upon exercise of options ($0.89 per share)

1

—

—

—

—

—
Shares issued upon exercise of options ($2.93 per share)

3

—

—

—

—

—
Fair value of stock issued in payment of accrued compensation

66

—

95

—

—

95
Fair value of stock options granted in payment of accrued compensation

—

—

12

—

—

12
Share based compensation

3

—

80

—

—

80
Shares issued through the use of At-The Market issuance ($1.24 average per share)

496

—

578

—

—

578
Shares issued for services ($1.93 per share)

4

—

7

—

—

7
Net loss

—

—

—

—

(1,490)

(1,490)
Balances at March 31, 2022

32,155

3

91,807

9

(84,255)

7,564

Share based compensation

—

—

50

—

—

50
Shares issued through the use of At-The Market issuance ($1.71 average per share)

5

—

9

—

—

9
Shares issued for services ($1.93 per share)

4

—

7

—

—

7
Shares issued in stock offering ($1.11 average per share)

4,186

1

4,210

—

—

4,211
Foreign-Exchange Translation Adjustment

—

—

—

(10)

—

(10)
Net loss

—

—

—

—

(1,638)

(1,638)
Balances at June 30, 2022

36,350

$
4

$
96,083

$
(1)

$
(85,893)

$
10,193

~~Table of Contents~~

Total ClearSign








Accumulated Other


Technologies Corp.

Common Stock

Additional

Comprehensive

Accumulated

Stockholders'

Noncontrolling

Total

Shares

Amount

Paid-In Capital

Income (loss)

Deficit

Equity

Interest

Equity
Balances at December 31, 2020

30,077

$
3

$
84,411

$
—

$
(74,874)

$
9,540

$
1

$
9,541
Shares issued upon exercise of options ($1.90 per share)

1

—

2

—

—

2

—

2
Shares issued upon exercise of options ($3.80 per share)

9

—

36

—

—

36

—

36
Shares issued upon exercise of options ($1.21 per share)

3

—

4

—

—

4

—

4
Shares issued upon exercise of options ($1.80 per share)

38

—

67

—

—

67

—

67
Fair value of stock options issued for board service

—

—

210

—

—

210

—

210
Fair value of stock issued in payment of accrued compensation

64

—

217

—

—

217

—

217
Share based compensation

—

—

410

—

—

410

—

410
Shares issued through the use of At-The Market issuance

941

—

4,469

—

—

4,469

—

4,469
Proceeds receivable from At-The Market issuance

—

—

(1,076)

—

—

(1,076)

—

(1,076)
Shares issued for services ($2.33 per share)

4

—

9

—

—

9

—

9
Net loss

—

—

—

—

(2,021)

(2,021)

—

(2,021)
Balances at March 31, 2021

31,137

3

88,759

—

(76,895)

11,867

1

11,868

Shares issued upon exercise of options ($3.10 per share)

17

—

54

—

—

54

—

54
Shares issued upon exercise of options ($0.89 per share)

42

—

36

—

—

36

—

36
Shares issued upon exercise of options ($1.85 per share)

3

—

6

—

—

6

—

6
Shares issued upon exercise of options ($1.21 per share)

95

—

72

—

—

72

—

72
Shares issued upon exercise of options ($0.98 per share)

23

—

—

—

—

—

—

—
Shares issued upon exercise of options ($2.93 per share)

6

—

—

—

—

—

—

—
Fair value of stock options issued for board service

—

—

52

—

—

52

—

52
Share based compensation

—

—

19

—

—

19

—

19
Shares issued through the use of At-The Market issuance

152

—

1,916

—

—

1,916

—

1,916
Shares issued for services ($2.33 per share)

4

—

9

—

—

9

—

9
Net loss

—

—

—

—

(2,290)

(2,290)

(1)

(2,291)
Balances at June 30, 2021

31,479

$
3

$
90,923

$
—

$
(79,185)

$
11,741

$
—

$
11,741


										Total ClearSign
						Accumulated Other				Technologies Corp.
	Common Stock			Additional		Comprehensive		Accumulated		Stockholders'
	Shares	Amount		Paid-In Capital			Income (Loss)	Deficit		Equity
Balances at December 31, 2021	31,582	$	3	$	91,035	$	9	$	(82,765)	$	8,282
Shares issued upon exercise of options ($0.89 per share)	1		—		—		—		—		—
Shares issued upon exercise of options ($2.93 per share)	3		—		—		—		—		—
Fair value of stock issued in payment of accrued compensation	66		—		95		—		—		95
Fair value of stock options granted in payment of accrued compensation	—		—		12		—		—		12
Share based compensation	3		—		80		—		—		80
Shares issued through the use of At-The Market issuance ($1.24 average per share)	496		—		578		—		—		578
Shares issued for services ($1.93 per share)	4		—		7		—		—		7
Net loss	—		—		—		—		(1,490)		(1,490)
Balances at March 31, 2022	32,155	$	3	$	91,807	$	9	$	(84,255)	$	7,564

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

ClearSign Technologies Corporation and Subsidiary

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

For the Six Months Ended June 30,


2022

2021

Cash flows from operating activities:

Net loss

$
(3,128)

$
(4,312)

Adjustments to reconcile net loss to net cash used in operating activities:

Common stock issued for services

14

18

Share based compensation

130

691

Depreciation and amortization

72

92

Estimated losses on contracts

—

574

Gain from sale of fixed assets

(37)

—

Gain on forgiveness of Payroll Protection Program Loan and interest

—

(251)

Change in operating assets and liabilities:

Contract assets

(448)

(590)

Accounts receivable

33

—

Prepaid expenses and other assets

(260)

(81)

Accounts payable and accrued liabilities

102

6

Accrued compensation and related taxes

175

225

Contract liabilities

—

(46)

Net cash used in operating activities

(3,347)

(3,674)

Cash flows from investing activities:





Acquisition of fixed assets

(5)

(25)

Disbursements for patents and other intangible assets

(73)

(69)

Proceeds from sale of fixed assets

37

—

Net cash used in investing activities

(41)

(94)

Cash flows from financing activities:





Proceeds from issuance of common stock, net of offering costs

4,798

5,309

Proceeds from exercise of stock options and warrants

—

277

Net cash provided by financing activities

4,798

5,586

Effect of exchange rate changes on cash and cash equivalents

(10)

—

Cash and cash equivalents:

Net change in cash and cash equivalents

1,400

1,818

Cash and cash equivalents, beginning of period

7,607

8,824

Cash and cash equivalents, end of period

$
9,007

$
10,642

Supplemental disclosure of cash flow information:

Officer and employee equity awards for prior year accrued compensation

$
107

$
217


(in thousands)	For the Three Months Ended March 31,
	2023		2022
Cash flows from operating activities:
Net loss	$	(1,429)	$	(1,490)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for services		3		7
Share-based compensation		242		80
Depreciation and amortization		80		36
Gain from sale of fixed assets		(5)		(23)
Right of use asset amortization		43		35
Realized gain from marketable securities		(20)		—
Lease Amendments		(14)		—
Change in operating assets and liabilities:
Contract assets		16		(205)
Accounts receivable		29		6
Prepaid expenses and other assets		51		(56)
Accounts payable and accrued liabilities		57		22
Accrued compensation and related taxes		1		85
Contract liabilities		392		—
Net cash used in operating activities		(554)		(1,503)

Cash flows from investing activities:
Acquisition of fixed assets		—		(5)
Disbursements for patents and other intangible assets		(24)		(33)
Proceeds from sale of fixed assets		5		23
Purchases of held-to-maturity short-term US treasuries		(2,162)		—
Redemption of held-to-maturity US treasuries		1,627		—
Net cash used in investing activities		(554)		(15)

Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering costs		—		578
Taxes paid related to vesting of restricted stock units		(15)		—
Net cash (used in) provided by financing activities		(15)		578
Cash and cash equivalents:
Net change in cash and cash equivalents		(1,123)		(940)
Cash and cash equivalents, beginning of period		6,451		7,607
Cash and cash equivalents, end of period	$	5,328	$	6,667

Supplemental disclosure of cash flow information:
Officer and employee equity awards for prior year accrued compensation	$	234	$	107
Prior year prepaid expenses repurposed to fixed assets as demonstration equipment	$	209	$	—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

ClearSign Technologies Corporation

Notes to Unaudited Condensed Consolidated Financial Statements

Note 1 – Organization and Description of Business

ClearSign Technologies Corporation (“ClearSign” or the “Company”) designs and develops products and technologies that have been shown to significantly improve key performance characteristics of industrial and commercial systems, including operational performance, energy efficiency, emission reduction, safety, and overall cost-effectiveness. The Company’s patented technologies are designed to be embedded in established OEM products as ClearSign Core™ and ClearSign Eye™ and other sensing configurations in order to enhance the performance of combustion systems and fuel safety systems in a broad range of markets. These markets include energy (upstream oil production and down-stream refining), commercial/industrial boiler, chemical, petrochemical, transport and power industries. The Company’s primary technology is its ClearSign Core technology, which achieves very low emissions without the need of ~~external flue gas recirculation,~~ selective catalytic ~~reduction, or higher excess air operation.~~reduction.

The Company was incorporated in the State of Washington in 2008. During January 2022, the Company relocated its headquarters from Seattle, Washington to Tulsa, Oklahoma. On July 28, 2017, the Company incorporated a subsidiary, ClearSign Asia Limited, in Hong Kong to represent the Company’s business and technological interests throughout Asia. Through ClearSign Asia Limited, the Company has established a Wholly Foreign Owned Enterprise (WFOE) in China – ClearSign Combustion (Beijing) Environmental Technologies Co., LTD.

Unless otherwise stated or the context otherwise requires, the terms ClearSign and the Company refer to ClearSign Technologies Corporation and its subsidiary, ClearSign Asia Limited.

Liquidity

The Company's condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As of March 31, 2023, the Company’s cash and cash equivalents totaled $5,328 thousand, and short-term held-to-maturity investments totaled $3,161 thousand, which is sufficient to fund current operating expenses beyond twelve months from the date hereof. The Company’s technologies are currently in field development, but with nominal fully operational commercial installations, and have generated nominal revenues from operations to date to meet operating expenses. In order to generate meaningful revenues, the technologies must be fully developed, gain market recognition and acceptance, and develop a critical level of successful sales and product installations.

Historically, the Company has financed operations primarily through issuances of equity securities. Since inception, the Company has raised approximately ~~$89.2~~$91.0 million in gross proceeds through the sale of its equity securities. During the ~~six~~three months ended ~~June 30, 2022,~~March 31, 2023, the Company ~~raised approximately $4.8 million in net~~did not raise proceeds ~~by issuing approximately 4.7 million shares~~through the issuance of common stock. Subsequent to the six months ended June 30, 2022, the Company raised additional funds by selling approximately 1.5 million shares to clirSPV, LLC, which resulted in net cash proceeds of $1.7 million. Refer to Note 6 – Equity for further details.

The Company has incurred losses since its inception totaling ~~$85.9~~$90.0 million and expects to experience operating losses and negative cash flows for the foreseeable future. Management believes that the successful growth and operation of the Company’s business is dependent upon its ability to obtain adequate sources of funding through co-development agreements, strategic partnering agreements, or equity or debt financing to adequately support product commercialization efforts, protect intellectual property, form relationships with strategic partners, and provide for working capital and general corporate purposes. There can be no assurance that the Company will be successful in achieving its long-term plans as set forth above, or that such plans, if consummated, will result in profitable operations or enable the Company to continue in the long-term as a going concern.

Table of Contents

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, ~~2021~~2022 has been derived from the Company’s audited financial statements as of that date.

In the opinion of management, these condensed consolidated financial statements reflect all normal recurring and other adjustments necessary for a fair presentation. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year or any other future periods.

The accompanying unaudited condensed consolidated financial statements include the accounts of ClearSign and its subsidiary. Intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Revenue Recognition and Cost of Sales

The Company recognizes revenue and related cost of goods sold in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Topic 606 Revenue from Contracts with Customers (“ASC 606”). When applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the performance obligations are satisfied. Revenues and cost of goods sold are recognized once the goods or services are delivered to the customer’s control or non-refundable performance obligations are satisfied. The Company’s contracts with customers generally have performance obligations and a schedule of non-refundable cancellation obligations. The contracts generally will be fully performed upon delivery of certain drawings or equipment. Revenue related to the contracts is recognized following the completion of non-refundable performance obligations as defined in the contract.

The Company’s contracts generally include progress payments from the customer upon completion of defined milestones. As these payments are received, they are offset against accumulated project costs and recorded as either contract assets or contract liabilities. Upon completion of the performance obligations and collectability is determined, revenue is recorded. For any contract that is expected to incur costs in excess of the contract price, the Company accrues the estimated loss in full in the period such determination is made.

Contract ~~Acquisition~~ Costs ~~and Practical Expedients~~

~~For contracts that have a duration of less than one year, the~~The Company ~~follows ASC 606,~~ ~~Narrow Scope Improvements and Practical Expedients~~~~, and expenses those~~capitalizes project costs ~~when incurred. For contracts with a life exceeding one year, the Company records those costs when~~until performance obligations related to the contract are completed. The Company ~~generally~~ expenses ~~sales commissions~~selling and marketing expenses when ~~incurred. The Company amortizes those costs~~incurred within the statements of operations in general and administrative ~~expenses over the life of the contract.~~expenses.

Table of Contents

Product Warranties

The Company warrants all installed products against defects in materials and workmanship for a period specified in each contract by replacing failed parts. Accruals for product warranties are based on historical or expected warranty experience and current product performance trends and are recorded as a component of cost of sales at the time revenue is recognized. The warranty liabilities are reduced by material and labor costs used to replace parts over the warranty period in the periods in which the costs are incurred. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary, and such adjustments could be material in the future if estimates differ significantly from actual warranty expense. Product warranties are included in accounts payable and accrued liabilities in the consolidated balance sheets.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash on deposit in a checking and savings ~~account.~~account, and short-term money market instruments with an original maturity of three months or less. Cash equivalents, which consist of short-term U.S. treasury bills, are based on quoted market prices, a Level 1 fair value measure.

Short-Term Investments

Short-term investments consist of U.S. treasuries with original maturities of twelve months or less and greater than three months. These short-term investments are classified as held to maturity and are recorded on an amortized cost basis based on the Company’s positive intent and ability to hold these securities to maturity. As of March 31, 2023, the Company has not experienced any other-than-temporary impairment of its short-term investments. A decline in the market value of any held-to-maturity security below cost that is deemed other than temporary results in a reduction in carrying amount to fair value. The impairment is charged to earnings and a new cost basis for the security is established. The company evaluates whether the decline in fair value of its investments is other-than temporary at each quarter-end.

The cost basis for the Company’s short-term investments totaled approximately $3,161 thousand and $2,606 thousand as of March 31, 2023 and December 31, 2022, respectively. The unrealized holding gains for the Company’s short-term investments totaled approximately $33 thousand and $4 thousand as of March 31, 2023 and December 31, 2022, respectively. The Company has not experienced any continuous unrealized holding losses on these investments. The fair value for the Company’s short-term investments totaled approximately $3,194 thousand and $2,610 thousand as of March 31, 2023 and December 31, 2022, respectively.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivables are recorded at the contractual invoiced amount. An allowance for doubtful accounts is established, as necessary, based on past experience and management’s judgment. The determination of the collectability of amounts due from customers require the Company to make judgments regarding future events and trends. Allowances for doubtful accounts are determined based on assessing the Company’s portfolio on an individual customer and on an overall basis. This process consists of a review of historical collection experience, current aging status of the customer accounts, and the financial condition of the Company’s customers. Based on a review of these factors, the Company may establish or adjust the allowance for specific customers and the accounts receivable portfolio as a whole.

Fixed Assets and Leases

Fixed assets are recorded at cost. Leases are recorded in accordance with FASB ASC 842, Leases. For those leases with a term greater than one year, the Company recognizes a right-of-use asset, which is included in fixed assets, net on the consolidated balance sheets, and a lease liability measured at the present value of the lease payments at the time of the lease inception or modification. Lease costs are recognized in the ~~income~~consolidated statement of operations over the lease term on a straight-line basis. Leases with a term of ~~one~~1 year or less are considered short term leases with rent expense recognized over the lease term. Depreciation is computed using the straight-line method over the estimated useful lives of the respective lease assets. Leasehold improvements are depreciated over the life of the lease or their useful life,

Table of Contents

whichever is shorter. All other fixed assets are depreciated over three to four years. Maintenance and repairs are expensed as incurred.

~~Table of Contents~~

Patents and Trademarks

Third-party expenses related to patents and trademarks are recorded at cost, less accumulated amortization. Amortization is computed using the straight-line method over the estimated useful lives of the assets once they are awarded. Patent application costs are deferred pending the outcome of patent and trademark applications. Costs associated with unsuccessful patent applications and abandoned intellectual property are expensed when determined to have no continuing value in current business activity. The Company evaluates the recoverability of the carrying values of intangible assets each reporting period.

Impairment of Long-Lived Assets

The Company tests long-lived assets, consisting of fixed assets, patents, trademarks, and other intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable through the estimated undiscounted cash flows expected from the use and eventual disposition of the assets. In the event an asset is not fully recoverable, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Fair value is determined based on the present value of estimated expected cash flows using a discount rate commensurate with the risks involved, quoted market prices, or appraised values depending upon the nature of the assets. Losses on long-lived assets to be disposed are determined in a similar manner, except those fair values are reduced for the cost of disposal.

Fair Value of Financial Instruments

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities measured at fair value are categorized based on whether or not the inputs are observable in the market and the degree that the inputs are observable. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The three levels of inputs used to establish fair value are the following:

●

Level 1 – Quoted prices in active markets for identical assets or liabilities;

●

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

●

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s financial instruments primarily consist of cash equivalents, short-term investments, accounts receivable, accounts payable, and accrued expenses. As of the balance sheet dates, the estimated fair values of the financial instruments were not materially different from their carrying values as presented on the balance sheets. This is primarily attributable to the short-term nature of these instruments.

The Company did not identify any other recurring or non-recurring assets and liabilities that are required to be presented in the balance sheets at fair value.

~~Table of Contents~~

Research and Development

The cost of research and development is expensed as incurred. Research and development costs consist of salaries, benefits, share based compensation, consumables, and consulting fees, including costs to develop and test prototype equipment and parts. Research and Development costs have been offset by funds received, if any, from strategic partners

Table of Contents

in cost sharing, collaborative projects. During the ~~six~~three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and June 30, 2021,~~ the Company did not receive ~~any~~ funds from these arrangements.

Government Assistance

The Company has adopted Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832) Disclosures by Business Entities about Government Assistance, which requires footnote disclosure of assistance received from government entities. The Company records gross monies received from government entities in other income, and associated expenses such ~~arrangements~~as salaries and supplies are recorded in Research and Development or General and Administration, depending on the nature of expenditure. The Company accrues for reimbursement requests submitted to ~~partially offset funding for research and development activities.~~government entities in accounts receivable.

Income Taxes

The Company accounts for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not the Company would not be able to realize their benefits, or that future deductibility is uncertain. Tax benefits are recognized only if it is more likely than not that the tax benefits will be utilized in the foreseeable future.

Share-Based Compensation

The costs of all employee stock options, as well as other equity-based compensation arrangements, are reflected in the unaudited condensed consolidated financial statements based on the estimated fair value of the awards on the grant date. That cost is recognized over the period during which an employee is required to provide service in exchange for the award, or in the case of performance options, expense is recognized upon completion of ~~a milestone~~milestones as defined in the grant agreement. Share-based compensation for stock grants to non-employees is determined as the fair value of the consideration received or the fair value of equity instruments issued, whichever is more reliably measured.

Foreign Operations

The accompanying unaudited condensed consolidated balance sheets as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021~~2022 include assets amounting to approximately ~~$182~~$277 thousand and ~~$274~~$172 thousand, respectively, relating to operations of ClearSign Asia Limited. The Beijing registered capital requirement is $350 thousand, which is required to be paid by 2027, and of which ~~none~~$111 thousand has been paid ~~to date.~~as of March 31, 2023. It is always possible that unanticipated events in foreign countries could disrupt the Company’s operations, and since the first quarter of 2020 this has been and currently continues to be the case with the effects of the ~~recent~~ COVID-19 pandemic.

Foreign Currency

Assets and liabilities of ClearSign Asia Limited with non-U.S. Dollar functional currency are translated to U.S. Dollars using exchange rates in effect at the end of the period. Revenue and expenses are translated to U.S. Dollars using rates that approximate those in effect during the period. The resulting translation adjustments are included in the Company’s condensed consolidated balance sheets in the stockholders’ equity section as a component of accumulated other comprehensive income (loss).

~~Noncontrolling Interest~~

The subsidiary of the Company has a minority shareholder agreement representing an ownership interest of 1.00% of ClearSign Asia Limited. The Company accounts for this noncontrolling interest pursuant to FASB ASC 810 whereby gains and losses in a subsidiary with a noncontrolling interest are allocated to the noncontrolling interest based on the ownership percentage of the noncontrolling interest, even if that allocation results in a deficit noncontrolling interest balance.

~~Table of Contents~~

Net Loss per Common Share

Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include additional common shares available upon exercise of stock options and warrants using the treasury stock method, except for periods for which no common share equivalents are included because their

Table of Contents

effect would be anti-dilutive. At ~~June 30,~~March 31, 2023 and March 31, 2022, ~~and December 31, 2021,~~ potentially dilutive shares outstanding amounted ~~3.4~~to 3.7 million and 3.3 million, respectively.

Recently Issued Accounting Pronouncements Adopted

In June 2017, the FASB issued an Accounting Standards Update (“ASU”) ASU 2016-13, Financial Instruments (Topic 326) Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. The standard replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. ASU 2016-13, and related amendments, are effective for fiscal years beginning after December 15, 2022. The Company ~~has~~adopted this standard on January 1, 2023. This standard did not ~~completed its assessment of the standard but does not expect the adoption to~~ have a material impact on ~~its~~the Company’s condensed consolidated financial statements.

~~In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832):~~ ~~Disclosures by Business Entities about Government Assistance~~, which outlines disclosure requirements for entities that receive assistance from a government body. ASU 2021-10, and related amendments, are affective for annual reports beginning after December 15, 2021. The Company does not expect the adoption to have a material impact on its financial statements.

Note 3 – Fixed Assets

Fixed Assets

Fixed assets are summarized as follows:


	June 30,		December 31,		March 31,		December 31,
(in thousands)	2022		2021		2023		2022
Machinery and equipment	$	393	$	722	$	209	$	390
Office furniture and equipment		173		218		60		177
Leasehold improvements		192		192		43		192
		758		1,132		312		759
Accumulated depreciation and amortization		(689)		(1,055)		(81)		(697)
		69		77		231		62
Operating lease ROU assets, net		408		453		284		322
Total	$	477	$	530	$	515	$	384

Depreciation and amortization expense for the ~~six~~three months ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021 totalled $13~~totaled $40 thousand and ~~$20~~$7 thousand, respectively.

Leases

The Company leases office space in Seattle, Washington, Tulsa, Oklahoma and Beijing, China. During June 2022, the Company entered into a new lease agreement for its Beijing office space for a period of one ~~year. We~~year with monthly rent at approximately $2 thousand. The Company classified this lease as an operating lease since it is more likely than not the lease will be renewed at the end of its term. ~~Prior to entering into this new lease agreement, the monthly rent for the old Beijing office space was approximately~~ ~~$5 thousand, equating to a short term lease expense of $23 thousand for the six months ended June 30, 2022.~~

During March 2023, the Company amended its Seattle lease to extend the lease term to September 2023. The amended lease reduced the square footage and lowered the monthly payment to approximately $4 thousand. The Company increased the right of use asset by $5 thousand and decreased the lease liability by $9 thousand. The Seattle, Tulsa, and Beijing leases are classified as operating leases, with remaining terms ranging from ~~one~~six months to six years; contractual language requires renewal negotiations to occur at or near termination. These leases are normal and customary for office space, in that, contractual guarantees exist requiring the lessee to return the premises to its original functional state. The Company accrued a liability of $2 thousand and $87 thousand as of March 31, 2023 and December 31, 2022, respectively, for the estimated cost of the restoration of the Seattle office. The Company plans to exit the Seattle lease on or before contract termination as part of the Company’s headquarters move from Seattle to Tulsa.

The Tulsa lease contains fixed annual lease payments that increase annually by 2%. The Seattle, Tulsa, and Beijing total monthly minimum rent is approximately $11 thousand. Operating lease costs for the three months ended March 31, 2023 and 2022 were $48 thousand and $57 thousand, respectively.

1110

Table of Contents

customary for office space, in that, contractual guarantees exist requiring the lessee to return the premises to its original functional state. In 2021, the Company accrued an estimated cost of $32 thousand to prepare for the restoration of the Seattle office. The Company plans to exit the Seattle lease on or before contract termination as part of our headquarters move from Seattle to Tulsa. In preparation for this move, the Company entered into the Tulsa operating lease agreement in April 2021.

The Seattle and Tulsa leases contain fixed annual lease payments that increase annually by factors that range between 2% to 3%. The Seattle, Tulsa, and Beijing total monthly minimum rent is approximately $22 thousand. Contractual agreements contain expiration dates ranging from less than ~~twelve months~~ ~~to less than six years.~~

Supplemental balance sheet information related to operating leases is as follows:


		June 30,		December 31,		March 31,			December 31,
(in thousands)		2022		2021		2023			2022
Operating lease ROU assets, net	$	408	$	453	$	284		$	322
Lease Liabilities:
Current lease liabilities	$	227	$	205	$	77		$	133
Long term lease liabilities		252		350		213			226
Total lease liabilities	$	479	$	555	$	290		$	359

Weighted average remaining lease term (in years):						2.7
Weighted average discount rate:						5.2	%


	~~June 30,~~
	~~2022~~
~~Weighted average remaining lease term (in years):~~	~~2.4~~
~~Weighted average discount rate:~~	~~5.8~~	%

Operating lease costs for the three and six months ended June 30, 2022 are $46 thousand and $88 thousand, respectively. Operating lease costs for the three and six months ended June 30, 2021 are $61 thousand and $96 thousand, respectively.


	For the Six Months Ended				For the Three Months Ended
Supplemental cash flow information related to leases is as follows:	June 30,
					March 31,
		2022		2021		2023		2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows used in operating leases	$	119	$	124	$	66	$	57
Non-cash impact of new leases and lease modifications
New operating lease liabilities	$	25	$	320
Change in operating lease liabilities					$	(9)	$	—
Change in operating lease ROU assets					$	5	$	—

Minimum future payments under the Company’s lease liabilities as of ~~June 30, 2022~~March 31, 2023 are as follows:


	Discounted		Payments		Discounted		Payments
	lease		due under		lease		due under
(in thousands)	liability		lease		liability		lease
	payments		agreements		payments		agreements
2022 (remaining 6 months)	$	131	$	143
2023		122		136	$	64	$	73
2024		54		65		54		65
2025		59		66		59		66
2026		63		67		63		67
Thereafter		50		51
2027						50		51
Total	$	479	$	528	$	290	$	322

At ~~June 30, 2022, $49~~March 31, 2023, $32 thousand of ~~our~~the Company’s future minimum lease payments ~~represented~~represents interest.

1211

Table of Contents

Note 4 – Patents and Other Intangible Assets

Patents and other intangible assets are summarized as follows:


	June 30,		December 31,		March 31,		December 31,
(in thousands)	2022		2021		2023		2022
Patents
Patents pending	$	509	$	439	$	330	$	307
Issued patents		577		577		815		815
		1,086		1,016		1,145		1,122
Trademarks
Trademarks pending		3		3		7		6
Registered trademarks		96		94		95		95
		99		97		102		101
Other		8		8		8		8
		1,193		1,121		1,255		1,231
Accumulated amortization		(381)		(322)		(473)		(433)
	$	812	$	799	$	782	$	798

Future amortization expense associated with issued patents and registered trademarks as of ~~June 30, 2022~~March 31, 2023 is as follows:


(in thousands)
2022 (remaining 6 months)	$	59
2023		96	$	108
2024		74		126
2025		42		96
2026		9		61
2027				39
Thereafter		12		7
	$	292	$	437

The amortization life for patents ranges between three to five years, with trademark lives set at ten years. The Company does not amortize patents or trademarks classified as pending.

During the ~~six~~three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ the Company assessed its patent and trademark assets. The Company also evaluated its strategic approach to the pursuit and protection of its intellectual property. It is the intent of the Company to continue to pursue intellectual property protection.

If the Company identifies certain assets where the intellectual property does not directly align with its core technology, the Company will impair the intangible asset and write-off the asset ~~to research and development~~as an expense.

Note 5 – Revenue, Contract Assets and Contract Liabilities

The Company recognized 0$894 thousand of revenues and $788 thousand of cost of goods sold during the three ~~and six~~ months ended ~~June 30, 2022.~~March 31, 2023. The revenue and cost of goods sold relate predominately to the Company’s process burner product line, where the Company successfully completed a burner performance customer witness test, which represented a contractual performance obligation per ASC 606.

The Company ~~recognized 0~~ did not recognize revenue ~~during~~or cost of goods sold for the three months ended ~~June 30, 2021. The Company recognized~~ ~~$363 thousand during the six months ended June 30, 2021 from the completion and delivery of a multi burner product contract with an infrastructure company.~~March 31, 2022.

~~During the three and six months ended June 30, 2021, the~~The Company ~~recognized cost~~had contract assets of ~~goods sold of $505~~$4 thousand and ~~$730~~$20 thousand at March 31, 2023 and December 31, 2022, respectively. ~~Cost~~The Company had contract liabilities of ~~sales during the three months ended June 30, 2021 consisted of $556~~$639 thousand ~~in estimated losses on 2 contracts that the Company anticipates will show losses upon completion. This was offset by adjustments totaling $35~~and $247 thousand ~~related to the reversal of an accrual for product warranty that expired on a completed project from the year 2018,~~at March 31, 2023 and ~~$16 thousand in adjustments for residual cost accruals. Cost of sales during the six~~December 31, 2022, respectively.

1312

Table of Contents

months ended June 30, 2021 consisted of cost of goods sold of $250 thousand, including a $36 thousand warranty accrual, recorded upon completion of the burner contract, and $574 thousand in estimated losses on 2 contracts that the Company anticipates will show losses upon completion. The recognized cost of goods sold was offset by adjustments totaling $86 thousand related to the reversals of accruals for product warranties that expired on 4 completed projects from the year 2018, and $8 thousand in adjustments for residual cost accruals.

~~The Company had contract assets of $486 thousand and $39 thousand at June 30, 2022 and December 31,~~ ~~2021, respectively. The Company had contract liabilities of~~ ~~$84 thousand at June 30, 2022 and December 31, 2021.~~

Note 6 – Equity

Common Stock and Preferred Stock

The Company is authorized to issue 62.5 million shares of common stock and 2.0 million shares of preferred stock. Preferences, limitations, voting powers and relative rights of any preferred stock to be issued may be determined by the Company’s Board of Directors. The Company has not issued any shares of preferred stock.

In July 2018, the Company completed a private equity offering and executed a Stock Purchase Agreement with clirSPV LLC (“clirSPV”) which permits participation in future capital raising transactions (the “Participation Right”) on the same terms as other investors participating in such transactions. In no event may the Participation Right be exercised to the extent it would cause clirSPV ~~LLC~~ or any of its affiliates to beneficially own 20% or more of the Company’s then outstanding common ~~stock or hold shares with 20% or more of the voting power.~~stock. In May 2022, the Company signed an agreement with clirSPV, ~~LLC,~~ that provides for an election right to extend the Participation Right beyond the original expiration date of December 31, 2023, but to no later than June 30, 2027. This election is pursuant to specific terms and conditions and expires on December 31, 2023.

On June 1, 2022, the Company completed a firm commitment underwritten public offering pursuant to an underwriting agreement, dated May 27, 2022, by and between the Company and Newbridge Securities Corporation by issuing 4,186 thousand shares of common stock at a price to the public of $1.11 per share, resulting in gross proceeds of approximately $4.6 million and net cash proceeds of approximately $4.2 million.

The Company has an At-The-Market (“ATM”) Offering Sales Agreement with Virtu Americas LLC, as sales agent pursuant to which it may currently sell shares of common stock with an aggregate offering price of up to $8.7 million. During the ~~six~~three months ended ~~June 30, 2022,~~March 31, 2023, the Company issued ~~approximately~~ ~~501 thousand~~zero shares of its common stock ~~at an average price of $1.24 per share for gross proceeds of approximately $624 thousand and net cash proceeds of approximately $587~~ ~~thousand.~~from the ATM program. As of ~~June 30, 2022,~~March 31, 2023, the Company has cumulatively issued approximately 1.6 million shares of common stock under the ATM program, at an average price of $3.84 per share. Gross proceeds totaled approximately $6.1 million and net cash proceeds was approximately $5.9 million.

The Company is currently subject to the SEC’s “baby shelf rules,” which prohibits companies with a public float of less

than $75 million from issuing securities under a shelf registration statement in excess of one-third of such company’s

public float in a 12-month period. These rules may limit future issuances of shares by the Company under its shelf

registration statement on Form S-3, the ATM Offering Sales Agreement or other securities offerings.

Equity Incentive Plan

On June 17, 2021, the Company's shareholders approved and the Company adopted the ClearSign Technologies Corporation 2021 Equity Incentive Plan (the “2021 Plan”) which permits the Company to grant Incentive Stock Options, Non-statutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, and Performance Shares, to eligible participants, which includes employees, directors and consultants. The Compensation Committee of the Board of Directors is authorized to administer the 2021 Plan.

~~Table of Contents~~

The 2021 Plan provides for an annual increase in available shares equal to the ~~lessor~~lesser of (i) 10% of the aggregate number of shares of Common Stock issued by the Company in the prior fiscal year; or (ii) such number provided by the Compensation Committee; provided, however, that the total cumulative increase in the number of shares available for issuance pursuant to this automatic share increase shall not exceed 400 thousand shares of common stock. In ~~2022,~~2023, the board of directors approved an increase of ~~150,423 shares.~~400,000 shares available for issuance pursuant to future awards in accordance with the terms of the 2021 Plan.

Ending balances offor the ~~Plans are~~2021 Plan is as follows:


	June 30,	December 31,	March 31,	December 31,
(in thousands)	2022	2021	2023	2022
Outstanding options and restricted stock units	3,358	3,076	3,332	3,202
Reserved but unissued shares under the Plans	2,706	2,901	2,530	2,777
Total authorized shares under the Plans	6,064	5,977	5,862	5,979

Table of Contents

Stock Options

Under the terms of the 2021 Plan, incentive stock options and nonstatutory stock options must have an exercise price at or above the fair market value on the date of the grant. At the time of grant, the Company will determine the period within which the option may be exercised and will specify any conditions that must be satisfied before the option vests and may be exercised. The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model.

As permitted by SEC Staff Accounting Bulletin (SAB) 107, management utilized the simplified approach to estimate the expected term of the options, which represents the period of time that options granted are expected to be outstanding. Expected volatility has been determined through the Company’s historical stock price volatility. The Company has not made an estimate of forfeitures at the time of the grant, but rather accounts for forfeitures at the time they occur. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield in effect at the time of grant. The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.

~~The following weighted-average assumptions~~During the three months ended March 31, 2023, no new options were ~~utilized in~~awarded by the ~~calculation of the fair value of stock options:~~company.


	~~June 30,~~
	~~2022~~
~~Expected life~~	~~5.71 years~~
~~Weighted average volatility~~	~~77.64~~	%
~~Weighted average risk-free interest rate~~	~~1.39~~	%
~~Expected dividend rate~~	0	%

Compensation expense associated with stock option awards for the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022 totaled ~~$15~~$44 thousand and ~~$57 thousand, respectively. Compensation expense associated with stock option awards for the three and six months ended June 30, 2021 totaled $19 thousand and $429~~$42 thousand, respectively.

~~Table of Contents~~

A summary of the Company’s stock option activity and changes is as follows:


	June 30,				March 31,
	2022				2023
(in thousands)	Options to Purchase Common Stock	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)	Options to Purchase Common Stock	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Outstanding at January 1	2,964	$	2.06	6.89
Outstanding at beginning of year					2,779	$	2.05	6.43
Granted	88	$	1.26	9.51	—	$	—	—
Exercised	(3)	$	0.89	—	—	$	—	—
Forfeited/Expired	(10)	$	2.93	—	—	$	—	—
Outstanding at June 30	3,039	$	2.03	6.47
Exercisable at June 30	2,212	$	1.71	5.79
Outstanding at end of period					2,779	$	2.05	6.18
Exercisable at end of period					2,011	$	1.70	5.68

The estimated aggregate pretax intrinsic value of the Company’s outstanding vested stock options at ~~June 30, 2022~~March 31, 2023 is ~~$291~~$27 thousand. The intrinsic value is the difference between the Company’s common stock price and the option exercise prices multiplied by the number of in-the-money options. This amount changes based on the fair value of the Company’s common stock.

At ~~June 30, 2022,~~March 31, 2023, there was ~~$1.7~~$1.0 million of total unrecognized compensation cost related to non-vested stock option-based compensation arrangements. Vesting criteria ranges from time-based to performance-based. The Company records costs for time-based arrangements ratably across the timeframe, whereas performance-based arrangements require management to continually evaluate predetermined goals against actual circumstances.

Restricted Stock Units

The Company ~~approved compensation for board service to be paid to its independent~~awards employees and directors in restricted stock units (“RSUs”) ~~under the 2021 Plan. Compensation is earned on a quarterly basis with the target value of compensation set at~~ $85 thousand per quarter. A RSU grant is to be awarded to each independent director in the beginning of the quarter in which services will be rendered, and the number of RSUs granted is to be based on the trading value of the Company’s stock on the date of the award.

The vesting of the RSU grants is contingent upon the occurrence of one of four future events which the Company cannot predict or control. Accordingly, stock based compensation has not been recognized for services performed during each of the six months ended June 30, 2022 or 2021 in accordance with FASB Accounting Standards Codification, ~~Topic 718~~~~, Compensation-Stock Compensation,~~ ~~(ASC 718). During the six months ended June 30, 2022, the Company issued~~ ~~110 thousand RSUs for board services amounting to $170 thousand of unrecognized compensation.~~

~~During January 2022, the Company issued retention bonuses for employees in the form of RSUs. These awards vest~~ ~~12 months~~ ~~from the date of award for services rendered in 2022. During the six months ended June 30, 2022, the Company issued~~ ~~97 thousand RSUs to employees amounting to $70 thousand of recognized compensation and $70 thousand for unrecognized compensation.~~

~~Stock Grants~~

~~During the six months ended June 30, 2022, the Company issued 66 thousand shares of common stock with a fair value of $1.44 per share to its employees. These shares were issued~~ in lieu of cash payment for ~~payment of~~compensation. These awards are granted pursuant to the 2021 ~~accrued bonuses~~Plan. Employee vesting criteria is time based, and compensation expense is recognized ratably across the timeframe.

1614

Table of Contents

~~totaling $125 thousand that were recorded during~~Director vesting criteria is contingent upon the ~~year ended December 31, 2021. In addition,~~occurrence of one of four future events, which the Company ~~issued 3~~cannot predict or control. Therefore, compensation expense for director RSUs is not recognized until one of these four future events occur, which is in accordance with FASB Accounting Standards Codification, Topic 718, Compensation-Stock Compensation, (ASC 718). Unrecognized compensation expense for director services amounted to $68 thousand ~~shares~~and $85 thousand for the three months ended March 31, 2023 and 2022, respectively. Director compensation is earned on a ~~one-time $3~~quarterly basis with the target value of compensation set at approximately $85 thousand per quarter.

A summary of the Company’s RSUs activity and changes is as follows:


	March 31,
	2023
(in thousands)	Number of Shares	Weighted Average Grant Date Fair Value
Nonvested at beginning of year	423	$	1.49
Granted	374	$	0.69
Vested	(245)	$	1.34
Nonvested at end of period	552	$	1.01

A summary of the Company’s RSU compensation expense is as follows:


	For the Three Months Ended
	March 31,
(in thousands)	2023			2022
Compensation Expense	$	199	$	35
Weighted Average Value Per Share	$	1.25	$	1.44

Stock Awards

The Company awards employees stock in lieu of cash payment for compensation, typically to satisfy accrued bonus ~~to 1 employee in recognition~~compensation. The awards are granted from the Company’s 2021 Plan.


	For the Three Months Ended
	March 31,
	2023		2022
Fair value	$	234	$	98
Weighted Average Value Per Share	$	0.79	$	1.43

Table of ~~their performance.~~Contents

Consultant Stock Plan

The 2013 Consultant Stock Plan (the “Consultant Plan”) provides for the granting of shares of common stock to consultants who provide services related to capital raising, investor relations, and making a market in or promoting the Company’s securities. The Company’s officers, employees, and board members are not entitled to receive grants from the Consultant Plan. The Compensation Committee of the Board of Directors is authorized to administer the Consultant Plan and establish the grant terms. The Consultant Plan provides for ~~quarterly~~periodic increases in the ~~available~~ number of authorized shares available for issuance under the Consultant Plan on the first day of each of the Company’s fiscal quarters. The quarterly increases are equal to ~~the lesser of~~ 1% of any new shares subsequently issued by the Company ~~during the quarter immediately prior to the adjustment date~~ or such lesser amount as the Board of Directors shall determine.

The Consultant Plan activity and change is as follows:


	~~June 30,~~March 31,
(in thousands)	~~2022~~2023
Reserved but unissued shares ~~January 1~~at beginning of year		~~211~~196
Increases in the number of authorized shares		5
Grants		~~(8)~~(4)
Reserved but unissued shares at end of year		~~203~~197

The Consultant Plan compensation expense is summarized as follows:

For the Six Months Ended

June 30,

2022

2021
Compensation Expense

$
14

$
17
Weighted Average Value Per Share

$
1.93

$
2.33

~~Inducement Stock Options~~

Pursuant to the rules of The Nasdaq Stock Market, and in compliance with those rules, the Company may issue equity awards, including stock options, as an inducement to an individual to accept employment with the Company. Inducement awards need not be approved by the Company's shareholders. During the year ended December 31, 2019, the Company granted 341 thousand non-qualified stock options to its Chief Executive Officer. The fair value of the non-qualified stock options estimated on the date of grant using the Black-Scholes valuation model was $176 thousand. The compensation expense recognized for these awards for the six months ended June 30, 2022 and 2021 was 0 and $13 thousand, respectively.

Note 7 – Commitments and Contingencies

Litigation

From time to time the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties and an adverse result in any such matter may harm the Company’s business. As of the date of this report, the Company is not a party to any material pending legal proceedings or claims that the Company believes will have a material adverse effect on the business, financial condition or operating results.

Indemnification Agreements

The Company maintains indemnification agreements with ~~our~~its directors and officers that may require the Company to indemnify these individuals against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by law.

1716

Table of Contents

Note 8 – ~~The Paycheck Protection Program (PPP) Loan~~Government Assistance

On May 8, 2020, the Company obtained a loan in the amount of $251 thousand (the “PPP loan”) from Bank of America (the “Lender”), pursuant to the Paycheck Protection Program (the “PPP”) under the Coronavirus Aid, Relief, and Economics Security Act (the “CARES Act”) that was signed into law in March 2020. In accordance with the PPP,During 2022, the Company was ~~permitted~~awarded a research grant from the Department of Energy (“DOE”) for approximately $250 thousand with the completion occurring in March 2023. The purpose of the grant was to ~~use the PPP loan proceeds to fund designated expenses, including certain payroll costs, rent, utilities, and other permitted expenses.~~produce a research paper for a flexible fuel ultra-low NOx process burner capable of burning 100% hydrogen fuel. The ~~PPP loan was evidenced by a promissory note, dated effective May 1, 2020, issued by~~award allowed the Company to request reimbursements for expenditures such as labor, material, and administrative costs. During the ~~Lender. The PPP loan was unsecured with a 2-year term and bore interest at a rate of 1.00% per annum.~~three months ended March 31, 2023, the Company recognized $69 thousand in reimbursements from DOE. The Company ~~applied with~~did not recognize reimbursements from the ~~Small Business Administration, ("SBA")~~DOE for ~~loan forgiveness~~the three months ended March 31, 2022.

Beginning in ~~January 2021. Payments on this note were deferred by the Lender until the forgiveness status of the loan was ascertained. In the second quarter of~~ 2021, the Company received ~~documentation from~~funds relating to the ~~SBA stating that this loan was forgiven in full. As a result,~~Oklahoma 21^st Century Quality Jobs Act. The estimated duration of the program is up to 10 years and is designed to attract growth industries to Oklahoma. By reporting quarterly salary statistics and meeting agreed upon employment thresholds, the state remits benefit monies to the Company. For the three months ended March 31, 2023, the Company ~~recorded a $251~~recognized $24 thousand ~~gain on forgiveness of debt and accrued interest during~~in government assistance. During the three ~~and six~~ months ended ~~June 30, 2021.~~March 31, 2022, the Company had no government assistance from this program.

Note 9 – Subsequent Events

~~Subsequent~~The Company has evaluated subsequent events as of the date of this report, and has none to June 30, 2022, the Company issued approximately 1,592 thousand shares to clirSPV LLC, at a price per share of $1.11, resulting in net cash proceeds to the Company of approximately $1,742 thousand. This offering to clirSPV LLC was executed pursuant to the Participation Right as described above in Note 6 - Equity.report.

1817

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION CONTAINED IN THIS REPORT

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “would,” “should,” “could,” “may,” “will” or other similar expressions in this report. In particular, these include statements relating to future actions; prospective products, applications, customers, and technologies; future performance or results of any products; anticipated expenses; and future financial results. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. Factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to:

●

our limited cash, history of losses, and our expectation that we will continue to experience operating losses and negative cash flows in the near future;

●

our ~~limited operating history;~~ability to successfully develop and implement our technologies and achieve profitability;

●

~~emerging competition and advancing technology in~~ our ~~industry that may outpace our technology;~~limited operating history;

●

changes in government regulations that could substantially reduce, or even eliminate, the need for our technology;

●

emerging competition and rapidly advancing technology in our industry that may outpace our technology;

●

customer demand for the products and services we develop;

●

the impact of competitive or alternative products, technologies, and pricing;

●

our ability to manufacture any products we design;

●

general economic conditions and events and the impact they may have on us and our potential customers;

●

our doing business in China and related risks with respect to intellectual property protection, currency exchange, contract enforcement, ~~and~~ rules on foreign ~~investment;~~investment and pandemic era regulations;

●

the impact of a cybersecurity incident or other technology disruption;

●

our ability to protect our intellectual property;

●

our ability to obtain adequate financing in the future;

●

our ability to retain and hire personnel with the experience and talent to develop our products and business;

●

~~general economic conditions and events and the impact they may have on us and our potential customers;~~

●

~~our ability to obtain adequate financing in the future to support our operations;~~

●

lawsuits, investigations, and other claims by third parties or regulatory agencies, including but not limited to, the Securities and Exchange Commission, Internal Revenue Service, Financial Industry Regulatory Authority;

●

the financial and operational impacts of the coronavirus pandemic on our business and results of operations, including impacts on our day-to-day operations, collaborative arrangements, revenue and marketing efforts and suppliers;

~~Table of Contents~~

●

our success at managing the risks involved in the foregoing items; and

●

other factors discussed in this report and in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K.

Forward-looking statements may appear throughout this report, including, without limitation, Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” The forward-looking statements are based upon management’s beliefs and assumptions and are made as of the date of this report. We undertake no obligation to publicly update or revise any forward-looking statements included in this report. You should not place undue reliance on these forward-looking statements.

Unless otherwise stated or the context otherwise requires, the terms “ClearSign,” “we,” “us,” “our” and the “Company” refer to ClearSign Technologies Corporation and its subsidiary, ClearSign Asia Limited.

Table of Contents

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited consolidated condensed financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q as well as our audited financial statements and related notes included in our most recent Annual Report on Form 10-K. In addition to historical information, this discussion and analysis here and throughout this Form 10-Q contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements due to a number of factors, including but not limited to, the risks described in the section titled “Risk Factors” in our Annual Report on Form ~~10-K.~~10-K for the year ended December 31, 2022.

~~OVERVIEW~~Overview

We design and develop technologies for the purpose of improving key performance characteristics of combustion systems, including emission and operational performance, energy efficiency and overall cost-effectiveness. Our ClearSign Core™ technology has been proven in full scale industrial test furnaces and boilers and first customer installations are currently operating in normal commercial ~~use.~~applications. We have generated nominal revenues from operations to date to meet operating expenses.

We have incurred losses since inception totaling ~~$85.9~~$90.0 million and we expect to experience operating losses and negative cash flow for the foreseeable future. We have historically financed our operations primarily through issuances of equity securities. Since inception, we have raised approximately ~~$89.2~~$91.0 million in gross proceeds through the sale of our equity securities. We may need to raise additional capital in the future, however, the significant volatility in the capital markets may negatively affect our ability to raise this additional capital.

It is not possible at this time to estimate the full impact that the coronavirus pandemic will have on our business or on our potential customers, suppliers, or other business partners. However, the continued spread of the coronavirus, the measures taken by the governments of affected countries, actions taken to protect employees, the limitations placed on travel and border crossings, and the impact of the pandemic on various business activities in affected countries could adversely impact our operational results and financial condition.

In order to generate meaningful revenues, our technologies must gain market recognition and acceptance to develop sufficient recurring sales. In addition, management believes that the successful growth and operation of our business is dependent upon our ability to obtain adequate sources of funding through co-development agreements, strategic partnering agreements, or equity or debt financing to support commercialization of our research and development efforts, protect intellectual property, form relationships with strategic partners and provide for working capital and general corporate purposes. There can be no assurance that we will be successful in achieving our long-term plans, or that such plans, if consummated, will result in profitable operations or enable us to continue in the long-term as a going concern.

~~Table of Contents~~

With respect to our China operations, we have a satellite office located in Beijing, China to support our commercialization efforts. At this time, these operations in China are immaterial compared to total company operations. As of ~~June 30, 2022,~~March 31, 2023, our China asset balance totaled ~~$182~~$277 thousand, or approximately 2%3%, compared to our total asset balance of $~~11,397~~$10,167 thousand. During the ~~year~~three months ended ~~December~~March 31, ~~2021, revenues attributable to~~2023 and 2022, our China operations ~~were $21 thousand, or approximately 3.4% compared to our total revenues of $607 thousand.~~reported zero revenues.

Our costs include employee salaries and benefits, compensation paid to consultants, materials and supplies for prototype development and manufacture, costs associated with development activities including materials, sub-contractors, travel and administration, legal and accounting expenses, sales and marketing costs, general and administrative expenses, and other costs associated with an early stage, publicly traded technology company. We currently have 1416 full-time employees. Because using third party expertise and resources is more efficient than maintaining full time resources, we also expect to incur ongoing consulting expenses related to technology development and some administrative, sales and legal functions commensurate with our current level of activities.

The amount that we spend for any specific purpose may vary significantly, and could depend on a number of factors including, but not limited to, the pace of progress of our commercialization and development efforts, actual needs with respect to product testing, development and research, market conditions, and changes in or revisions to our sales and marketing strategies.

Table of Contents

Research, development, and commercial acceptance of new technologies are, by their nature, unpredictable. Although we undertake development and commercialization efforts with reasonable diligence, there can be no assurance that the net proceeds from our securities offerings will be sufficient to enable us to develop our technology to the extent needed to create sufficient future sales to sustain operations. If the net proceeds from these offerings are insufficient for this purpose, we will consider other options to continue our path to commercialization, including, but not limited to, additional financing through follow-on equity offerings, debt financing, co-development agreements, sale or licensing of developed intellectual or other property, or other alternatives.

We cannot assure that our technologies will be accepted, that we will ever earn revenues sufficient to support our operations, or that we will ever be profitable. Furthermore, we have no committed source of financing, and we cannot assure that we will be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required to scale back our development ~~plans~~ by reducing expenditures for employees, consultants, business development and marketing efforts or to otherwise severely curtail, or even to cease, our operations.

~~CRITICAL ACCOUNTING POLICIES~~Critical Accounting Policies

The following discussion and analysis of financial condition and results of operations is based upon our financial statements, which have been prepared in conformity with accounting principles generally accepted in the United States of America. Certain accounting policies and estimates are particularly important to the understanding of our financial position and results of operations. These policies and estimates require the application of significant judgment by management. These estimates can be materially affected by changes from period to period as economic factors and conditions outside of our control change. As a result, they are subject to an inherent degree of uncertainty. In applying these policies, our management uses their judgment to determine the appropriate assumptions to be used in the determination of certain estimates. Those estimates are based on our historical operations, our future business plans and projected financial results, the terms of existing contracts, our observance of trends in the industry, information provided by our customers and information available from other outside sources, as appropriate. See Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this report for a more complete description of our significant accounting policies.

Revenue Recognition and Cost of Goods Sold.

The Company recognizes revenue and related cost of goods sold in accordance with FASB ASC 606 Revenue from Contracts with Customers (ASC 606). Revenues and cost of goods sold are recognized once the goods or services are delivered to the customer’s control or non-refundable performance obligations are satisfied. The Company’s

~~Table of Contents~~

contracts with customers generally have performance obligations and a schedule of non-refundable cancellation obligations. The contracts generally will be fully performed upon delivery of certain documents or equipment. Revenue related to the contracts is recognized following the completion of non-refundable performance obligations as defined in the contract.

The Company’s contracts generally include progress payments from customers upon completion of defined milestones. As these payments are received, they are offset against accumulated project costs and recorded as either contract assets or contract liabilities. Upon completion of the performance obligations and collectability is determined, revenue can be recorded. For any contract in connection with which the Company is expected to incur costs in excess of the contact price, the Company accrues the estimated loss in full in the period such determination is made.

Impairment of Long-Lived Assets

The Company tests long-lived assets, consisting of fixed assets, patents, and other intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable through the estimated undiscounted cash flows expected from the use and eventual disposition of the assets. In the event an asset in not fully recoverable a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Fair value is determined based on the present value of estimated expected cash flows using a discount rate commensurate with the risks involved, quoted market prices, or appraised values

Table of Contents

depending upon the nature of the assets. Losses on long-lived assets to be disposed of is determined in a similar manner, except those fair values are reduced for the cost of disposal.

Product Warranties

The Company warrants all installed products against defects in materials and workmanship, and shortcomings in performance compared to contractual guarantees for a period specified in each contract. Accruals for product warranties are based on expected warranty experience and current product performance trends which are recorded as a component of cost of sales at the time revenue is recognized. The warranty liabilities are reduced by material and labor costs during the warranty period in the periods in which the costs are incurred. The Company periodically assesses the adequacy of our recorded warranty liabilities and adjusts the amounts as necessary, and such adjustments could be material if estimates differ significantly from actual warranty expense. The warranty liabilities are included in accounts payable and accrued liabilities in the unaudited condensed consolidated balance sheets.

Research and Development

The cost of research and development is expensed as incurred. Research and development costs consist of salaries, benefits, share based compensation, consumables, and consulting fees, including costs to develop and test prototype equipment and parts. Research and development costs are offset by any funds received from strategic partners in cost sharing, collaborative ~~projects or government grants.~~projects.

Stock-Based Compensation

The costs of all employee stock options, as well as other equity-based compensation arrangements, are reflected in the unaudited, condensed consolidated financial statements based on the estimated fair value of the awards on the grant date. That cost is recognized over the period during which an employee is required to provide service in exchange for the award, or in the case of performance options, expense is recognized upon completion of a milestone as defined in the grant agreement. Stock-based compensation for stock grants to non-employees is determined as the fair value of the consideration received or the fair value of equity instruments issued, whichever is more reliably measured.

Fair Value of Financial Instruments

The Company's financial instruments primarily consist of cash equivalents, accounts payable, accrued expenses and short-term investments in government securities. As of the balance sheet date, the estimated fair values of the

~~Table of Contents~~

financial instruments were not materially different from their carrying values as presented on the consolidated balance sheets. This is primarily attributed to the short maturities of these instruments.

Table of Contents

RESULTS OF OPERATIONS

Comparison of the Three ~~and Six~~ Months Ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~

Highlights of our quarter financial performance are as follows:

For the Three Months Ended

(in thousands, except per share data)

June 30,

2022

2021

$ Change

% Change
Revenues

$
—

$
—

$
-

NA
%
Cost of goods sold

—

505

$
(505)

100.0
%
Gross loss

—

(505)

$
505

100.0
%
Research and development

188

472

$
(284)

60.2
%
General and administrative

1,472

1,565

$
(93)

5.9
%
Operating Expenses

1,660

2,037

$
(377)

18.5
%
Other income, net

22

251

$
(229)

91.2
%
Net loss

$
(1,638)

$
(2,290)

$
652

28.5
%
Basic and diluted net income per common share

$
(0.05)

$
(0.07)

$
0.02

28.6
%


	For the Six Months Ended								For the Three Months Ended
(in thousands, except per share data)	June 30,								March 31,
	2022		2021		$ Change		% Change		2023		2022		$ Change		% Change
Revenues	$	—	$	363	$	(363)	100.0	%	$	894	$	—	$	894	NM
Cost of goods sold		—		730	$	(730)	100.0	%		788		—	$	788	NM
Gross loss		—		(367)	$	367	100.0	%
Gross profit (loss)										106		—	$	106	NM
Research and development		296		1,298	$	(1,002)	77.2	%		160		108	$	52	48.1	%
General and administrative		2,881		2,898	$	(17)	0.6	%		1,650		1,409	$	241	17.1	%
Operating Expenses		3,177		4,196	$	(1,019)	24.3	%		1,810		1,517	$	293	19.3	%
Other income, net		49		251	$	(202)	80.5	%		275		27	$	248	918.5	%
Net loss	$	(3,128)	$	(4,312)	$	1,184	27.5	%	$	(1,429)	$	(1,490)	$	61	(4.1)	%
Basic and diluted net income per common share	$	(0.09)	$	(0.14)	$	0.05	35.7	%	$	(0.04)	$	(0.05)	$	0.01	(20.0)	%
NM = Not meaningful

Sales and Gross Profit

Consolidated revenues ~~were zero~~ for the three months ended ~~June 30, 2022 and 2021.~~

~~Consolidated revenues~~March 31, 2023 were $894 thousand compared to zero for the six months ended June 30, 2022, were zero compared to revenues of $363 thousand for six months ended June 30, 2021. During the six months ended June 30, 2021, consolidated revenues included revenues from our burner product line for a sale that occurredsame period in ~~the United States.~~

~~Gross loss~~2022. Revenues for the three months ended ~~June 30, 2022, decreased~~March 31, 2023 are mostly related to our process burner product line and an associated burner performance test. The associated burner performance test satisfied a contractual performance obligation, per ASC 606 standards, that required our customer to witness a successful burner performance test that meet their engineering specifications.

Gross profit for the three months ended March 31, 2023, increased by ~~$505~~$106 thousand, ~~or 100.0%,~~ compared to the three months ended ~~June 30, 2021.~~March 31, 2022. During the three months ended ~~June 30, 2021, negative~~March 31, 2023, gross profit ~~occurred~~was generated predominantly ~~due~~by our successful process burner performance test, which allowed us to ~~recognizing estimated contract losses from our ExxonMobil project.~~recognize revenues and associated profit.

Gross loss for the six months ended June 30, 2022, decreased by $367 thousand, or 100.0%, compared to the six months ended June 30, 2021. During the six months ended June 30, 2021, negative profit from our estimated ExxonMobil contract losses were offset by positive profit from our burner product line saleOperating Expenses

Operating expenses consist of research and ~~reversals of product warranties that expired.~~development (R&D) and general and administrative (G&A) expenses. These are addressed separately below.

Research and Development

Research and development (“R&D”) expenses ~~decreased~~remained relatively consistent year-over-year.

General and Administrative

General and administrative (“G&A”) expenses increased by ~~$284~~$241 thousand, or approximately ~~60.2%~~17.1%, to ~~$188~~$1,650 thousand for the three months ended ~~June 30, 2022,~~March 31, 2023, as compared to ~~$472~~$1,409 thousand during the three months ended ~~June~~March 31, 2022. During the three months ended March 31, 2023, G&A expenses were unfavorably impacted by $187 thousand, due to vesting of restricted stock units triggered by the departure of a board director.

2322

Table of Contents

Other Income

~~30, 2021. During~~

Other income for the three months ended ~~June 30, 2022, R&D expenses decreased due~~March 31, 2023 was $275 thousand as compared to an organizational restructure that occurred at the beginning of 2022. We restructured our organization such that three engineers previously performing R&D functions were reassigned to business development functions, which shifted salaries of approximately $174 thousand to G&A expense. This reassignment occurred at the beginning of 2022 and will affect the remainder of the year, and was executed to focus engineers on sales initiatives related to customer technical support. Decreases in human capital costs also favorably impacted R&D expenses by $123$27 thousand for the three months ended ~~June 30,~~March 31, 2022, ~~when compared to~~or an approximate 918.5% increase. The sale of materials from the ~~three months ended June 30, 2021.~~

R&D expenses decreased by $1,002 thousand, or approximately 77.2%, to $296 thousand for the six months ended June 30, 2022, as compared to $1,298 thousand during the six months ended June 30, 2021. During the six months ended June 30, 2022,decommissioning of our ~~organizational restructure~~Seattle office favorably impacted ~~R&D expenses~~other income by $281 thousand compared to the six months ended June 30, 2021. Decreases in human capital related to headcount reductions favorably impacted R&D expenses by $246 thousand for the six months ended June 30, 2022, when compared to the six months ended June 30, 2021. In additions, product development costs trended down by $181 thousand for the six months ended June 30, 2022 compared to the six months ended June 30, 2021, due to engineers focusing on business development functions.

~~General and Administrative~~

~~General and administrative (“G&A”) expenses decreased by $93 thousand, or approximately 5.9%, to $1,472~~$119 thousand for the three months ended ~~June 30, 2022, as compared to $1,565 thousand during~~March 31, 2023. Further, the three months ended June 30, 2021. A one-time severance accrual for our prior CFO during the three months ended June 30, 2021, favorably affected G&A by $100 thousand, when compared to the three months ended June 30, 2022. Board compensation decreased by $136 thousand in the three months ended June 30, 2022, when compared to the three months ended June 30, 2021. This compensation decrease was attributed to two key factors: (i) changing paymentreceipt of director compensation from stock options to restricted stock units, and (ii) deferring compensation expense as required by accounting standard ASC 718 Stock Compensation. Refer to Note 6 - Equity for further details. During the three months ended June 30, 2022, G&A expenses increased by $174 thousand compared to the prior three months ended June 30, 2021, duegovernment assistance monies related to our ~~organizational restructure referenced in the R&D explanation above.~~

G&A expenses decreased by $17 thousand, or approximately 0.6%, to $2,881 thousand for the six months ended June 30, 2022, as compared to $2,898 thousand during the six months ended June 30, 2021. Decreases in board compensation were offset by increases in G&A expenses for our organizational restructure during the six months ended June 30, 2022, when compared to the six months ended June 30, 2021.

~~Other Income~~

~~The impact~~Oklahoma Quality Jobs rebate agreement and Department of ~~the $251 thousand loan forgiveness during the three and six months ended June 30, 2021, primarily drove the unfavorable change when compared to the three and six months ended June 30, 2022.~~

~~The impact of selling fixed assets from our Seattle office location~~Energy grant favorably impacted other income by ~~$14 thousand and $37~~$93 thousand for the three months ~~and six~~ended March 31, 2023. Interest income from short-term investments favorably impacted other income by $58 thousand for the three months ended June 30, 2022, respectively. In January 2022, the board of directors approved the relocation of our headquarters from Seattle, Washington to Tulsa, Oklahoma. After approval, we began soliciting bids for our used lab and office equipment.March 31, 2023.

Net Loss

Net loss for the three months ended ~~June 30, 2022,~~March 31, 2023 was ~~$1,638~~$1,429 thousand as compared to ~~$2,290~~$1,490 thousand for the three months ended ~~June 30, 2021,~~March 31, 2022, or an approximate ~~28.5%~~4.1% decrease. The ~~$652~~$61 thousand decrease in net loss during the three months ended ~~June, 2022~~March 31, 2023, is primarily attributable to ~~zero~~the $106 thousand increase in gross profit ~~during~~referenced in the ~~three months ended June 30, 2022, compared to negative gross profit for the three months ended June 30, 2021.~~

Net loss for the six months ended June 30, 2022, was $3,128 thousand compared to $4,312 thousand for the six months ended June 30, 2021, or an approximate 27.5% decrease. The $1,184 thousand decrease in net loss during the

~~Table of Contents~~

~~three months ended June, 2022 is primarily attributable to decreased operating expenses during the six months ended June 30, 2022, when compared to the six months ended June 30, 2021.~~above explanation.

Liquidity and Capital Resources

At ~~June 30, 2022,~~March 31, 2023, our cash and cash equivalent balance totaled ~~$9,007~~$5,328 thousand compared to ~~$7,607~~$6,451 thousand at December 31, ~~2021,~~2022, a decrease of $1,123 thousand. At March 31, 2023, our short-term held-to-maturity investments totaled $3,161 thousand, which is an increase of ~~$1,400 thousand.~~$555 thousand compared to $2,606 at December 31, 2022.

At ~~June 30,~~ ~~2022,~~March 31, 2023, our current assets were in excess of current liabilities resulting in working capital of ~~$9,146~~$7,493 thousand as compared to ~~$7,293~~$8,586 thousand at December 31, ~~2021. During~~2022. We have no contractual debt obligations, and the ~~six months ended June 30, 2022,~~Company has sufficient working capital to fund current operating expenses for over twelve months. To the extent the Company requires additional funds more than 12 months from the date hereof, and customer cash collections cannot fund our needs, the Company may utilize equity offerings. Historically, the Company has ~~been~~ funded ~~with~~operations predominately through equity offerings.

Currently, the Company can sell shares of common stock through its ATM program. As of March 31, 2023, the remaining aggregate offering price for future sales of common stock on the ATM is approximately ~~$4,798 thousand in net cash proceeds from our equity offerings during 2022. Subsequent~~$8.7 million, subject to the ~~six~~SEC’s “baby shelf rules,” which prohibits companies with a public float of less than $75 million from issuing securities under a shelf registration statement in excess of one-third of such company’s public float in a 12-month period (for more details, see “Note 6 – Equity” in the notes to our condensed consolidated financial statements). Future sales of shares of common stock and the price at which we may be able to sell such shares of common stock under the ATM are dependent on factors beyond our control, including, but not limited to, market conditions, the trading price of our common stock and our capital needs.

We filed a Form S-3 shelf registration statement with the SEC on July 1, 2022 that was declared effective on August 12, 2022.The registration statement on Form S-3 allows us to offer common stock, preferred stock, warrants, subscription rights, debt securities and units from time to time, as market conditions permit to fund, to the extent required beyond the 12 months ~~ended June 30, 2022,~~from the date hereof, the ongoing operations of the Company. Until the growth of revenue increases to a level that covers operating expenses, the Company ~~raised an additional $1,742 thousand~~intends to continue to fund operations in ~~net cash proceeds by issuing approximately 1,592 thousand shares~~this manner, although, the volatility in the capital markets and potential upcoming recession may negatively affect our ability to ~~clirSPV LLC. This equity offering was made pursuant to a purchase right agreement between clirSPV LLC and the Company. Refer to Note 9 – Subsequent Events for further details.~~do so.

Operating activities for the ~~six~~three months ended ~~June 30, 2022,~~March 31, 2023, resulted in cash outflows of ~~$3,347~~$554 thousand, primarily due to the loss for the period of ~~$3,128~~$1,429 thousand, offset with non-cash expenses of ~~$179 thousand.~~$329 thousand, and an increase of $392 thousand of contract liabilities, which represents payments from customers in advance of future project costs.

Operating activities for the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, resulted in cash outflows of ~~$3,674~~$1,503 thousand, primarily due to the loss for the period of ~~$4,312~~$1,490 thousand, offset with non-cash expenses of ~~$1,124~~$135 thousand.

Table of Contents

Investing activities for the three months ended March 31, 2023 resulted in cash outflows of $554 thousand, which is primarily attributable to $2,162 thousand of short-term held-to-maturity U.S. treasury purchases offset by $1,627 thousand in redemption of the same investments.

Investing activities for the ~~six~~three months ended ~~June 30,~~March 31, 2022, resulted in cash outflows of ~~$78~~$38 thousand in disbursements for fixed and intangible assets, and cash inflows of ~~$37~~$23 thousand in proceeds from fixed asset ~~sales, compared to cash outflows of $94~~sales.

Financing activities for the three months ended March 31, 2023, included $15 thousand in disbursements for ~~fixed and intangible assets for the six months ended June 30, 2021.~~taxes paid related to vesting of employee restricted stock units.

Financing activities for the ~~six~~three months ended ~~June 30,~~March 31, 2022, included ~~$4,798~~$578 thousand in net proceeds from the sale of ~~501~~496 thousand shares of our common stock through our ATM program at an average price of $1.24 per ~~share, and sale of 4.2 million shares of our common stock through a public offering at an average price of $1.11 per~~ share.

Financing activities for the six months ended June 30, 2021, included $5,309 thousand in net proceeds from the sale of 1,093 thousand shares of our common stock at an average price of $5.03 per share through our ATM program. Financing activities for the six months ended June 30, 2021, also included $277 thousand from the exercise of option awards and warrants.

Off-Balance Sheet Transactions

We do not have any off-balance sheet transactions.

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to provide this information.

ITEM 4.CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), that are designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal accounting and financial officer, as appropriate, to allow timely decisions regarding required disclosure.

~~Table of Contents~~

We carried out an evaluation under the supervision and with the participation of management, including our Chief Executive Officer (principal executive officer) and our Vice President and Controller (principal accounting and financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures as of ~~June 30, 2022,~~March 31, 2023, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon the evaluation of our disclosure controls and procedures as of ~~June 30, 2022,~~March 31, 2023, our Chief Executive Officer (principal executive officer) and our Vice President and Controller (principal accounting and financial officer) concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter ended ~~June 30, 2022~~March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer (principal executive officer) and our Vice President and Controller (principal accounting and financial officer), does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems,

Table of Contents

no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II-OTHER INFORMATION

ITEM 1.LEGAL PROCEEDINGS

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

ITEM 1A.RISK FACTORS

We incorporate herein by reference the risk factors included under “Part I - Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, ~~2021~~2022, which we filed with the Securities and Exchange Commission on March 31, ~~2022,~~2023, and the risk factors included in the reports and other documents we filed with the Securities and Exchange Commission subsequent to that date. There are no material changes from the risk factors set forth in such prior filings, except as set forth below.

~~Macroeconomic pressures in~~If we fail to comply with the continued minimum closing bid requirement of The Nasdaq Capital Market LLC (“Nasdaq”) by October 30, 2023 or other requirements for continued listing, including stockholder equity requirements, our common stock may be delisted and the price of our common stock and our ability to access the capital markets ~~in which we operate may adversely affect our financial results.~~ could be negatively impacted.

~~Geopolitical issues around~~

Our common stock is listed for trading on Nasdaq, therefore, we must satisfy Nasdaq’s continued listing requirements, including, among other things, a minimum closing bid price requirement of $1.00 per share for 30 consecutive business days.

On November 1, 2022, the ~~world can impact macroeconomic conditions~~Company received notice from Nasdaq that the closing bid price for the Company’s common stock had been below $1.00 per share for the previous 30 consecutive business days, and ~~could have a material adverse impact~~that the Company was therefore not in compliance with the minimum bid price requirement for continued inclusion on ~~our financial results. For example,~~Nasdaq under Nasdaq Listing Rule 5550(a)(2) (the “Rule”). Nasdaq’s notice had no immediate effect on the ~~ultimate impact~~listing or trading of the ~~conflict in Ukraine~~Company’s common stock on ~~fuel prices, inflation,~~Nasdaq. The notice indicated that the ~~global~~Company had 180 calendar days, until May 1, 2023, to regain compliance with the Rule. We were not able to regain compliance within this 180-day period. On May 2, 2023, we were granted an additional compliance period of 180 calendar days, or until October 30, 2023, to regain compliance with the minimum closing bid requirement. The Company could regain compliance with the $1.00 minimum bid listing requirement if the closing bid price of its common stock is at least $1.00 per share for a minimum of ten (10) consecutive business days during the 180-day compliance period. To qualify for this additional compliance period of 180 calendar days, the Company was required to meet the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, except the bid price requirement, and provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.

There can be no assurance that we will be able to regain compliance with Nasdaq’s listing rules. If we are unable to regain compliance with the minimum closing bid price requirement or if we fail to meet any of the other continued listing requirements, including stockholder equity requirements, our securities may be delisted from Nasdaq, which

2625

Table of Contents

~~supply chain~~could reduce the liquidity of our common stock materially and other macroeconomic conditions is unknown and could materially adversely affect global economic growth, disrupting discretionary spending habits and generally decreasing demand for our products and services. While we do not purchase any of significant raw materials directly from Russia, it isresult in a ~~significant global producer of fuel, nickel, and copper. Disruptions~~corresponding material reduction in the markets for those inputs could negatively impact the world and domestic economy. We cannot predict the extent or duration of sanctions in response to the conflict in Ukraine, nor can we predict the effects of legislative or other governmental actions or regulatory scrutiny of Russia, Russia's other allies or other countries with which Russia has significant trade or financial ties, including China. The conflict in Ukraine may also exacerbate geopolitical tensions globally. While the demandprice of our ~~services~~common stock. In addition, delisting could harm our ability to raise capital on terms acceptable to us, or at all, and may result in the ~~U.S. has not yet been affected~~potential loss of confidence by ~~this conflict in Ukraine~~investors, employees and fuel prices, we cannot predict the impact that the conflict may have on future financial results. For example, domestic customers for some of our product lines may choose to reduce discretionary spending on goods and services such as ours until fuel and oil price volatility subsides.business development opportunities.

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On ~~June 30, 2022,~~March 27, 2023, we issued 3,750 shares of common stock at a price per share of ~~$1.93,~~$0.66, the closing price of our common stock on November ~~19, 2021,~~17, 2022, the date of grant, from our 2013 Consultant Stock Plan to our investor relations firm, Firm IR, for services provided during the three months ended ~~June 30, 2022.~~March 31, 2023. These shares were issued in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, for a transaction by an issuer not involving a public offering.

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4.MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.OTHER INFORMATION

None.

Table of Contents

ITEM 6.EXHIBITS

Exhibit
Number		Document

3.1		Articles of Incorporation of ClearSign Technologies Corporation (1)
3.2		Bylaws, as amended effective September 8, 2021 (2)
~~10.1*+~~10.1		~~Amendment to Employment Agreement between the Company and Colin James Deller~~Catharine de Lacy’s Offer Letter (3)
10.2		~~Purchase Right Waiver~~Form of ~~clirSPV LLC (3)~~Indemnification Agreement (4)+
31.1*		Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer
31.2*		Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer
32.1**		Section 1350 Certification of Principal Executive Officer and Principal Financial Officer
101.INS		Inline XBRL Instance Document*
101.SCH		Inline XBRL Taxonomy Extension Schema Document*
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

*Filed herewith

~~Table of Contents~~

**Furnished herewith

+ Agreement with management or compensatory plan or arrangement.

(1)	Incorporated by reference from the ~~registrant’s~~ Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission on November 13, 2019.

(2)	Incorporated by reference from the ~~registrant’s~~ Form 8-K filed with the Securities and Exchange Commission on September 10, 2021.

(3)	Incorporated by reference from Exhibit 10.1 of the ~~registrant’s~~ Form 8-K filed with the Securities and Exchange Commission on ~~May 31, 2022.~~February 24, 2023.

(4)	Incorporated by reference from Exhibit 10.18 of the Form S-1/A filed with the Securities and Exchange Commission on March 9, 2012.

2827

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		CLEARSIGN TECHNOLOGIES CORPORATION


Date: ~~August~~May 15, ~~2022~~2023	By:	/s/ Colin James Deller
		Colin James Deller
		Chief Executive Officer
		(Principal Executive Officer)




Date: May 15, 2023	By:	/s/ Brent Hinds
		Brent Hinds
		Vice President and Controller (Principal Financial and Accounting Officer)

2928


(in thousands)	For the Six Months Ended June 30,
	2022		2021
Cash flows from operating activities:
Net loss	$	(3,128)	$	(4,312)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for services		14		18
Share based compensation		130		691
Depreciation and amortization		72		92
Estimated losses on contracts		—		574
Gain from sale of fixed assets		(37)		—
Gain on forgiveness of Payroll Protection Program Loan and interest		—		(251)
Change in operating assets and liabilities:
Contract assets		(448)		(590)
Accounts receivable		33		—
Prepaid expenses and other assets		(260)		(81)
Accounts payable and accrued liabilities		102		6
Accrued compensation and related taxes		175		225
Contract liabilities		—		(46)
Net cash used in operating activities		(3,347)		(3,674)

Cash flows from investing activities:
Acquisition of fixed assets		(5)		(25)
Disbursements for patents and other intangible assets		(73)		(69)
Proceeds from sale of fixed assets		37		—
Net cash used in investing activities		(41)		(94)

Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering costs		4,798		5,309
Proceeds from exercise of stock options and warrants		—		277
Net cash provided by financing activities		4,798		5,586
Effect of exchange rate changes on cash and cash equivalents		(10)		—
Cash and cash equivalents:
Net change in cash and cash equivalents		1,400		1,818
Cash and cash equivalents, beginning of period		7,607		8,824
Cash and cash equivalents, end of period	$	9,007	$	10,642

Supplemental disclosure of cash flow information:
Officer and employee equity awards for prior year accrued compensation	$	107	$	217

For the Three Months Ended

March 31,

Compensation Expense

Weighted Average Value Per Share